Icosapent

Icosapent is a type of polyunsaturated fatty acid (PUFA) that is used in the treatment of hypertriglyceridemia, a condition characterized by high levels of triglycerides in the blood. It is also known as Icosapent ethyl or EPA ethyl ester.

Chemical Structure[edit | edit source]

Icosapent is a synthetic derivative of eicosapentaenoic acid (EPA), one of the two types of omega-3 fatty acids found in fish oil. It is an ethyl ester form of EPA, which means it has an additional ethyl group attached to the carboxyl end of the fatty acid. This modification increases the stability of the molecule and enhances its absorption in the body.

Pharmacology[edit | edit source]

Icosapent is metabolized in the liver where it is converted back to EPA. The exact mechanism of action of icosapent is not fully understood, but it is believed to reduce the production of triglycerides in the liver, increase the clearance of triglycerides from the blood, and reduce inflammation.

Clinical Use[edit | edit source]

Icosapent is used in the treatment of severe hypertriglyceridemia, a condition that increases the risk of pancreatitis and cardiovascular disease. It is also used as an adjunct to diet and exercise in patients with high cardiovascular risk to reduce triglyceride levels.

Side Effects[edit | edit source]

Common side effects of icosapent include gastrointestinal symptoms such as diarrhea, nausea, and abdominal pain. Less common side effects include rash, dizziness, and changes in taste.